E
Eva Goncalvesova
Researcher at Cardiovascular Institute of the South
Publications - 47
Citations - 3819
Eva Goncalvesova is an academic researcher from Cardiovascular Institute of the South. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 14, co-authored 40 publications receiving 2250 citations. Previous affiliations of Eva Goncalvesova include Comenius University in Bratislava & University College Dublin.
Papers
More filters
Journal ArticleDOI
Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction
Scott D. Solomon,John J.V. McMurray,Inder S. Anand,Junbo Ge,Carolyn S.P. Lam,Aldo P. Maggioni,Felipe Martinez,Milton Packer,Marc A. Pfeffer,Burkert Pieske,Margaret M. Redfield,Jean L. Rouleau,Dirk J. van Veldhuisen,Faiez Zannad,Michael R. Zile,Akshay S. Desai,Brian Claggett,Pardeep S. Jhund,Sergey Boytsov,Josep Comín-Colet,John G.F. Cleland,Hans-Dirk Düngen,Hans-Dirk Düngen,Eva Goncalvesova,Tzvetana Katova,José Francisco Kerr Saraiva,Małgorzata Lelonek,Béla Merkely,Michele Senni,Sanjiv J. Shah,Jingmin Zhou,Adel R. Rizkala,Jianjian Gong,Victor Shi,Martin Lefkowitz +34 more
TL;DR: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failureand an ejection fraction of 45% or higher, and among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit in patients with lower ejection fractions and in women.
Journal ArticleDOI
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.
Aldo P. Maggioni,Stefan D. Anker,Ulf Dahlström,Gerasimos Filippatos,Piotr Ponikowski,Faiez Zannad,Offer Amir,Ovidiu Chioncel,Marisa Crespo Leiro,Jarosław Drożdż,Andrejs Erglis,Emir Fazlibegovic,Candida Fonseca,Friedrich Fruhwald,Plamen Gatzov,Eva Goncalvesova,Mahmoud Hassanein,Jaromír Hradec,A Kavoliuniene,Mitja Lainscak,Damien Logeart,Béla Merkely,Marco Metra,Hans Persson,Petar M. Seferović,A. Temizhan,Dimitris Tousoulis,Luigi Tavazzi +27 more
TL;DR: To evaluate how recommendations of European guidelines regarding pharmacological and non‐pharmacological treatments for heart failure are adopted in clinical practice, a large number of patients with HF are receiving treatment according to these guidelines.
Journal ArticleDOI
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.
María G. Crespo-Leiro,Stefan D. Anker,Aldo P. Maggioni,Andrew J.S. Coats,Gerasimos Filippatos,Frank Ruschitzka,Roberto Ferrari,Massimo F Piepoli,Juan F. Delgado Jimenez,Marco Metra,Candida Fonseca,Jaromír Hradec,Offer Amir,Damien Logeart,Ulf Dahlström,Béla Merkely,Jarosław Drożdż,Eva Goncalvesova,Mahmoud Hassanein,Ovidiu Chioncel,Mitja Lainscak,Petar M. Seferovic,Dimitris Tousoulis,A Kavoliuniene,Friedrich Fruhwald,Emir Fazlibegovic,A. Temizhan,Plamen Gatzov,Andrejs Erglis,Cécile Laroche,Alexandre Mebazaa +30 more
TL;DR: The European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT‐R) was set up with the aim of describing the clinical epidemiology and the 1‐year outcomes of patients with heart failure with the added intention of comparing differences between countries.
Journal ArticleDOI
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
John R. Teerlink,Rafael Diaz,G. Michael Felker,John J.V. McMurray,Marco Metra,Scott D. Solomon,Kirkwood F. Adams,Inder S. Anand,Alexandra Arias-Mendoza,Tor Biering-Sørensen,Michael Böhm,Diana Bonderman,John G.F. Cleland,John G.F. Cleland,Ramón Corbalán,María G. Crespo-Leiro,Ulf Dahlström,Luis E. Echeverría,James C. Fang,Gerasimos Filippatos,Cândida Fonseca,Eva Goncalvesova,Assen Goudev,Jonathan G. Howlett,David E. Lanfear,Jing Li,M. Lund,Peter S. Macdonald,Viacheslav Mareev,Shin-ichi Momomura,Eileen O'Meara,Alexander Parkhomenko,Piotr Ponikowski,Felix José Alvarez Ramires,Pranas Šerpytis,Karen Sliwa,Jindrich Spinar,Thomas M. Suter,János Tomcsányi,Hans Vandekerckhove,Dragos Vinereanu,Adriaan A. Voors,Mehmet Yilmaz,Faiez Zannad,Lucie Sharpsten,Jason C. Legg,Claire Varin,Narimon Honarpour,Siddique Abbasi,Fady I. Malik,Christopher E. Kurtz +50 more
TL;DR: Among patients with heart failure and a reduced ejection, patients who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo.
Journal ArticleDOI
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study
Rolf Wachter,Michele Senni,Jan Belohlavek,Ewa Straburzyńska-Migaj,Klaus K. Witte,Zhanna Kobalava,Candida Fonseca,Eva Goncalvesova,Yuksel Cavusoglu,Alberto Fernandez,Said Chaaban,Ellen Bøhmer,Anne-Catherine Pouleur,Christian Mueller,Christophe Tribouilloy,Eva Lonn,Jehad A L Buraiki,Jacek Gniot,Maria Mozheiko,Małgorzata Lelonek,Adele Noe,H Schwende,W Bao,D Butylin,Domingo A. Pascual-Figal,Transition Investigators +25 more
TL;DR: To assess tolerability and optimal time point for initiation of sacubitril/valsartan in patients stabilised after acute heart failure (AHF), data are presented on rats for the first time.